Skip to content

Clinical Efficacy and Safety Assessment of Combined Uyghur Medicine Runfei San and Respiratory Training in Chronic Bronchitis Treatment

Efficacy Evaluation of Uyghur Medicine Runfei San Combined with Respiratory Training in the Treatment of Acute Exacerbation of Chronic Bronchitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002508
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-07-14
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Bronchitis

Interventions

Experimental Group:Respiratory training combined with Runfei San
Control Group A:Runfei San
Control Group B:Respiratory training

Sponsors

Uyghur Medical Hospital of Xinjiang Uyghur Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Fulfills the clinical diagnostic standards for chronic bronchitis as defined by Western medicine. (2) Conforms to the Uyghur medicine syndrome differentiation criteria for "Qidao Zhong" (airway swelling). (3) Age range: 18-85 years. (4) Patients are informed and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with chronic bronchitis complicated by severe infection. (2) Patients with concomitant severe diabetes mellitus, hypertension, hyperlipidemia, cerebral infarction, myocardial infarction, or other serious conditions. (3) Patients with mental disorders or neurological dysfunction. (4) Patients with malignant tumors. (5) Patients with thoracic diseases, pulmonary tuberculosis, or other lung diseases. (6) Patients with a history of pulmonary surgery. (7) Patients who have used relevant medications within 2 weeks prior to consultation. (8) Patients with a history of allergic reactions to medications used in this study. (9) Patients with poor treatment compliance that may affect therapeutic efficacy.

Design outcomes

Primary

MeasureTime frame
Inflammatory Markers;

Secondary

MeasureTime frame
6-Minute Walk Test;Blood Gas Results;Changes in Pulmonary Function;

Countries

China

Contacts

Public ContactAiliyaer Yasheng

Uyghur Medical Hospital of Xinjiang Uyghur Autonomous Region

18139603707@163.com18139603707

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026